divis
adjust ep yoy vs cent forecast
adjust ep increas record vs help lower tax rate
oper incom
ep estim record
ep estim introduc project
leader infect prevent equip report adjust ep vs
year earlier compar report year-over-year period yoy unless otherwis indic cent
estim oper incom ep benefit approxim tax rate vs
revenu increas million price contribut bp sale benefit
million custom built inventori ahead march brexit date pre-ord consum
life scienc segment conjunct move new facil constant currenc organ
growth revenu corpor total increas million
slip million ireland move corpor headquart ireland
avoid potenti tax issu brexit rose million
adjust gross profit rose million increas bp sale due price fx mix
product initi partial off-set higher labor cost tariff adjust sg expens equal
revenu vs expens equal revenu vs adjust oper
profit million revenu vs tax rate around vs
adjust net incom increas million net margin rose sale vs
pleas see import disclosur end report
healthcar product sale infect prevent procedur solut
healthcar provid world-wide includ capit equip washer steam ga steril surgic
tabl light clean chemistri relat mainten instal servic well consum
organ constant currenc basi million backlog rose yoy
million capit equip rose consum increas servic rose approxim
busi replac remain project consum track procedur volum
equip align building/rehab project oper profit increas million
group margin vs due increas volum favor mix oper effici
healthcar specialti servic rang specialti servic healthcar provid includ
hospit steril servic instrument scope repair linen manag organ
oper profit jump million vs million group margin vs
due higher volum improv product leverag invest made last sever
quarter although invest outsourc instrument reprocess continu impact
segment result depend level invest particular quarter smaller
outsourc project work gener return month well larger project involv build
new facil staf etc may take year reach optim margin start-up natur
longer term project ad lumpi
appli steril technolog ast contract steril laboratori servic medic
devic manufactur pharmaceut custom other million sale rose
organ increas volum segment core medic devic custom group oper profit
million group oper margin revenu vs due revenu
growth inflationari price includ busi contract steri
offset higher labor cost increas product
life scienc ls consist capit equip consum product washer steril
etc equip mainten specialti servic pharmaceut manufactur research
institut lumpi busi due variabl construct deliveri schedul rose organ
million capit equip declin given tough comp jump year ago consum
given pre-ord note servic ls backlog flat million ls longer
lead time ls oper profit rose million group margin vs due
higher volum cost manag consum highest margin follow servic
revenu increas organ constant currenc basi record billion vs
billion organ basi ast ls adjust
oper incom increas million margin bp yoy adjust
tax rate vs net incom million yoy net profit margin rose bp
sale adjust ep exclud special item rose record vs year
after-tax return averag equiti asset pre-tax invest capit respect
vs respect
balanc sheet march includ cash equival million equiti billion
debt billion provid debt-to-tot capit ratio vs slightli
ebitda comfort rang
pleas see import disclosur end report
divis wellington shield co llc
flow oper cfo quarter million vs million year earlier total
million vs million adjust net incom vs note activ
pipelin acquisit primarili tuck-in free cash flow project million vs million
due higher capital-expenditure plan see million share repurchas
quarter around million remain board author share repurchas use off-set
sale earn outlook
two-third busi routin replac capit spend visibl month
remain one-third construction/expans project month visibl hospit
non-hospit build ambulatori surgeri center micro hospit continu benefit new
product launch last month well anoth robust year new product anticip
ast expect grow manag target organ growth rate
ls growth modest level three year ago june ep estim vs
last year previous revenu million
ep estim vs record compani guidanc introduc
previou project revenu nearli billion target
constant currenc organ growth fiscal year fx current expect neutral result
revenu held back somewhat million plan product rationalization/manufactur
consolid compani guidanc anticip medic devic tax return last
occur earn neg impact million quarterli basi northwel partnership
northwel hospit group account surgic procedur new york project
expect gener approxim million revenu full-year run rate million
futur year model oper margin record vs
expect tariff/labor cost total around million fiscal year gross free
cash flow estim per share respect assum net incom million
million exclud intang amort around million alreadi deduct
adjust net incom figur capital-expenditure million million due million
invest plan expand global capac ast outsourc instrument reprocess capital-expenditure
mainten around million dividend million
ep estim introduc revenu billion assum
continu solid hospit spend manufactur consolid note expect save
million next two year primari benefit oper margin model
bp revenu long-term target organ growth double-digit ep
share trade forward ep estim project
year growth rate rate hold due valuat metric investor focus
strong fundament includ satisfactori hospit spend potenti outsourc margin
improv initi rel immun polit pressur healthcar compani may wish
aggress sell ev-to-ebitda ratio project ebitda
million project ebitda million share trade price-to-earnings ratio base upon
trail report ep current
pleas see import disclosur end report
divis wellington shield co llc
global hospit spend environ key variabl deriv approxim revenu
outsid subject compani increas geograph risk well vagari foreign currenc
fluctuat medic technolog compani product obsolesc and/or increas competit
relev risk regulatori issu continu import mani compani product process
subject fda approv and/or inspect
pleas see import disclosur end report
divis wellington shield co llc
march fiscal year-end
mm ex per share
good sold
good sold
compani report great lake review estim cleveland oh elliott schlang jason rodger
pleas see import disclosur end report
